Amiloride (MK-870): Epithelial Sodium Channel Inhibitor for Ion Channel and Endocytosis Research

Executive Summary: Amiloride (MK-870) is a small-molecule inhibitor targeting epithelial sodium channels (ENaC) and urokinase-type plasminogen activator receptors (uPAR) (APExBIO, product page). It acts as a prototypical ion channel blocker in sodium channel and cellular endocytosis research (Wang et al. 2018, DOI). Its specificity has been benchmarked in viral entry assays, showing no significant inhibition of clathrin-mediated endocytosis in CIK cells at standard concentrations (Wang et al. 2018). Amiloride’s use is central in mechanistic studies of cystic fibrosis and hypertension. Solutions of Amiloride require prompt use post-preparation and storage at -20°C for optimal stability (APExBIO, product documentation).

Biological Rationale

Amiloride (MK-870) is a selective inhibitor of epithelial sodium channels (ENaC), critical regulators of sodium balance in epithelial tissues. ENaC activity modulates ion transport in the kidney, lung, and other epithelia, impacting conditions such as cystic fibrosis and hypertension (related article). Amiloride also inhibits uPAR, linking sodium transport with cellular signaling and endocytosis pathways. Its dual mechanism enables dissection of sodium channel function and receptor-mediated cellular uptake in disease models. This extends the mechanistic landscape described in previous translational analyses by providing current, comparative benchmarking data.

Mechanism of Action of Amiloride (MK-870)

Amiloride binds directly to the pore of ENaC, blocking sodium influx in a voltage-independent manner. This inhibition is reversible and concentration-dependent, with IC₅₀ values typically in the low micromolar range (buffer-, cell type-, and temperature-dependent). In addition to ENaC, Amiloride antagonizes uPAR, modulating plasminogen activation and downstream signaling. At higher concentrations, Amiloride can inhibit other cation channels, but selectivity for ENaC is maintained at research-standard dosing (APExBIO BA2768). It also acts as a PC2 channel blocker, influencing calcium signaling in epithelial cells. The compound’s rapid cellular uptake and reversible binding make it suitable for acute mechanistic studies.

Evidence & Benchmarks

• Amiloride (MK-870) does not inhibit clathrin-mediated endocytosis of GCRV104 in CIK cells at standard research concentrations (Wang et al. 2018, DOI).
• It effectively blocks ENaC-mediated sodium transport in multiple epithelial tissue models at IC₅₀ values of 0.1–10 μM (APExBIO, product page).
• Amiloride inhibits uPAR-mediated signaling, impacting cellular adhesion and migration pathways (see mechanistic review).
• Optimal stability is maintained when stored at -20°C; solutions degrade rapidly at ambient temperature (APExBIO).
• No off-target inhibition observed for dynamin-dependent or pH-dependent viral entry pathways in benchmark aquatic virology models (Wang et al. 2018, DOI).

Applications, Limits & Misconceptions

Amiloride (MK-870) is widely used to dissect sodium channel function in disease-relevant models, including:

• Cystic fibrosis research: Probes ENaC activity in airway epithelia, linking sodium reabsorption and mucus viscosity.
• Hypertension models: Investigates renal ENaC involvement in blood pressure regulation.
• Cellular endocytosis modulation: Used as a negative control to differentiate clathrin-mediated from other endocytic mechanisms (Wang et al. 2018).

For a comprehensive experimental workflow, see this guide, which outlines troubleshooting and comparative advantages. This article updates those protocols by including the latest benchmarking data for aquatic viral models.

Common Pitfalls or Misconceptions

• Amiloride does not inhibit clathrin-mediated endocytosis at research-standard concentrations (Wang et al. 2018).
• It is ineffective against dynamin-dependent endocytic pathways or pH-dependent viral entry.
• Prolonged storage of Amiloride solutions (>24 h) at room temperature leads to degradation and unreliable results (APExBIO BA2768).
• Amiloride should not be used as a pan-endocytosis inhibitor; its action is selective for sodium channels and uPAR.
• Not for diagnostic or therapeutic human use. APExBIO’s Amiloride is intended strictly for research applications.

Workflow Integration & Parameters

Amiloride (MK-870) is supplied as a solid (C₆H₈ClN₇O, 229.63 g/mol) requiring dissolution in aqueous buffer or DMSO. Stock solutions should be prepared fresh, used promptly, and stored at -20°C (APExBIO). For ENaC inhibition, working concentrations typically range from 0.1 to 10 μM, with assay-specific optimization required. Shipping is performed with Blue Ice for small molecules to ensure integrity. Incorporating Amiloride into sodium channel research workflows allows for the validation of channel-specific phenomena and negative control comparisons in endocytosis assays. For expanded mechanistic context, see this strategic deployment analysis, which this dossier clarifies with new aquatic virology evidence.

Conclusion & Outlook

Amiloride (MK-870) remains a gold-standard tool for dissecting epithelial sodium channel and urokinase receptor signaling in research settings. APExBIO provides a high-purity, research-grade version (BA2768) for reproducible results. Its selectivity profile is well-characterized, limiting off-target effects in standard model systems. Future benchmarking and expanded disease modeling will further define its mechanistic boundaries and translational impact.